Gary Conrad
Cardiovascular Disease · Pasadena, CANPI 1669424271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,648 and has fallen 92.6% since, to $123 in 2025.
Across 149 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$525
- Novartis$483
- Pfizer$352
- Abbott$226
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
- Johnson & Johnson$197
- plus $1K from 21 others
Across 40 payments — averaging $3626.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$132K
- Novartis$14K
What the payments were for
- Food & beverage$3,124100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $525 |
| Novartis | 30 | $483 |
| Pfizer | 14 | $352 |
| Abbott | 12 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $206 |
| Johnson & Johnson | 12 | $197 |
| Amarin Pharma, Inc. | 3 | $181 |
| Bayer | 1 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $104 |
| Medtronic | 1 | $100 |
| Esperion Therapeutics, Inc. | 4 | $97 |
| AstraZeneca | 4 | $68 |
| Akcea Therapeutics, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| CMP Pharma, Inc. | 2 | $52 |
| Boehringer Ingelheim | 2 | $49 |
| Impulse Dynamics (USA) Inc. | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Edwards Lifesciences | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Gilead | 1 | $20 |
| Philips North America LLC | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Cleerly, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$123
- VYNDAQEL$121
- Vascepa$118
- Repatha$115
- Arctic Front$100
How this compares
$3,125 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 20 | $309 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Pasadena
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.